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Abstract
Introduction Cyclin E, a G1 cyclin essential for G1–S phase
transition, is known to have a profound effect on tumorigenesis.
Elevated levels of cyclin E have been associated with breast
cancer, and chromosomal instability observed in breast cancer
is suggested to be associated with constitutive expression of
cyclin E. It was previously demonstrated that SUM149PT human
breast cancer cells show very high levels of cyclin E expression
by western analysis and that they express a nonfunctional cyclin
E ubiquitin ligase due to a mutation in the F-box protein hCdc4.
Methods We examined cyclin E expression in both MCF10A
and SUM149PT cells using western blot analysis and flow
cytometry. Immunofluorescence was utilized for the localization
of cyclin E in both normal and breast cancer cells. In addition,
array comparative genomic hybridization analysis was
performed to compare chromosome copy number alterations
with levels of cyclin E expression among a panel of breast
cancer cell lines.
Results SUM149PT cells overexpress cyclin E on a cell per cell
basis for the duration of the cell cycle. High cyclin E levels are
maintained throughout the S phase, and SUM149PT cells
exhibit an S phase delay or arrest probably due to cyclin E
overexpression. In addition, comparative genomic hybridization
indicated that SUM149PT cells exhibit many chromosome copy
number alterations, which may reflect prior or ongoing genomic
instability. However, no direct correlation was observed
between cyclin E levels and genomic copy number alteration in
a panel of human breast cancer cell lines.
Conclusions Cyclin E is overexpressed at high levels
throughout the cell cycle in SUM149PT cells, which is in stark
contrast to cyclin E degradation observed in the mid to late S
phase of normal cells. SUM149PT cells are unable to regulate
cyclin E and also exhibit many copy number alterations.
However, there was a lack of direct correlation between cyclin
E overexpression and chromosomal instability across a panel of
other breast cancer cell lines examined.
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Introduction
Cyclin E is a G1 cyclin that complexes with cyclin-depend-
ent kinase 2 to regulate cell transit from the G1 phase to the
S phase of the cell cycle. Under normal conditions, cyclin E
accumulates in the nucleus at the G1/S phase boundary
and is degraded as cells progress through the S phase [1-
3]. This firm regulation of cell growth by cyclin E is often lost
in cancer. Many human breast cancers have cyclin E
present constitutively in an active cyclin-dependent kinase
2 complex, and a correlation between cyclin E overexpres-
sion and human breast cancer has been demonstrated
[4,5].
Failure to properly regulate cyclin E can lead to phosphor-
ylation of substrates at inappropriate times during the cell
cycle, consequently eliminating important checkpoint con-
trols. Accelerated S phase entry, tumorigenesis and
genetic instability have all been found to be consequences
of cyclin E deregulation [6-9]. Constitutive expression of
cyclin E may lead to chromosomal instability, as proper reg-
ulation of cyclin E is critical for the fidelity of chromosome
transmission. Defective regulation of these processes can
produce chromosomal aberrations, and it has been shown
that overexpression of cyclin E induces chromosomal ane-
uploidy in human mammary epithelial (HME) cells [8].
aCGH = array comparative genomic hybridization; BSA = bovine serum albumin; FITC = fluorescein isothiocyanate; HME = human mammary epithe-
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Regulation of cyclin E is dependent upon SCF ubiquitin
ligase activity [10,11]. SCF is a ubiquitin ligase that targets
a number of proteins, including cyclin E, for ubiquitin-medi-
ated proteolysis. SCF has three main subunits: Skp1,
Cdc53/Cul-1, and Rbx1 [12]. An F-box protein forms the
variable component, which determines the substrate spe-
cificity of the SCF ubiquitin ligase. SCF was first suggested
to be involved in cyclin E degradation when levels of cyclin
E were found to be elevated in Cul-1-/- embryos [11,12].
When three thermosensitive mutants of the most charac-
terized F-box proteins in yeast were examined, the cdc4
mutant was the only one to stabilize cyclin E [13]. In addi-
tion, a dominant negative hCdc4 allele transduced into KB
cells led to the accumulation of cyclin E [13]. The F-box
protein hCdc4 therefore appears to be the critical compo-
nent for cyclin E turnover in normal cells.
Western blot analysis of cyclin E protein levels in a panel of
breast cancer cell lines demonstrated that SUM149PT
breast cancer cells possess extremely high levels of cyclin
E. The SUM149PT cell line has also been shown to pos-
sess a mutation at the hCdc4 locus, eliminating the last four
of seven WD40 repeats thought to be important for inter-
action with the SCF ubiquitin ligase [13,14]. Taken
together, these results make this cell line a good model for
investigating cyclin E regulation and its association with
chromosomal instability in breast cancer.
Since cyclin E is normally degraded as cells enter the S
phase, it is still uncertain whether the high levels of cyclin E
protein in SUM149PT cells observed by western blot anal-
ysis are due to a high proportion of the population stabiliz-
ing normal levels, or whether cyclin E is overexpressed to
high levels on a per cell basis.
In the present article, we demonstrate that cyclin E is highly
overexpressed on a per cell basis in the SUM149PT cell
line relative to a large panel of human breast cancer cell
lines. We further show that this overexpression remains
throughout the cell cycle. Very high cyclin E levels are main-
tained throughout the S phase, which is in stark contrast to
cyclin E degradation observed in the mid to late S phase of
normal cells. In addition, we also observed an accumulation
of cells in the S phase of the cell cycle that may be a direct
effect of cyclin E overexpression. We found overexpression
of cyclin E in the nucleus and in the cytoplasm of
SUM149PT cells, whereas cyclin E was centralized at low
levels to the nucleus in normal cells. While SUM149PT
cells did exhibit many DNA copy number aberrations, a
direct correlation with cyclin E overexpression and the
number of genomic aberrations, as determined by array
comparative genomic hybridization (aCGH), was not
observed in the panel of breast cancer cells we examined.
Materials and methods
Materials, cell lines, and culture conditions
MCF10A cells were maintained in SFIHE medium (Ham's
F-12 with 5% BSA [Gibco, Carlsbad, CA, USA], 0.5 µg/ml
fungizone, 5 µg/ml gentamycin, 5 mM ethanolamine, 10
mM HEPES, 10 µM transferrin, 10 µM 3,3,'5-Triiodo-L-Thy-
ronine (T3), 50 µM sodium selenite, 5 µg/ml insulin, 1 µg/
ml hydrocortisone, and 10 ng/ml epidermal growth factor
(EGF). SUM149PT cells were maintained in 5% IH (Ham's
F-12 with 5% fetal bovine serum [Gibco] with 5 µg/ml insu-
lin and 1 µg/ml hydrocortisone).
The culture conditions for the immortalized normal cell line
MCF10A and the human breast cancer cell lines (SUM44,
SUM52, SUM102, SUM149PT, SUM152, SUM190,
SUM225, SUM229 and SUM1315MO2) were as
described previously [15]. All cells were cultured at 37°C
in a humidified incubator containing 10% CO2 and were
maintained free of mycoplasm.
Western blot analysis
Whole cell lysates were prepared using RIPA lysis buffer
(1% deoxycholic acid, 1% Triton X-100, 0.1% SDS, 250
mM NaCl and 50 mM Tris–HCl, pH 7.5) and were soni-
cated. The whole cell lysates were cleared by centrifuga-
tion and the amounts of protein were quantified by
performing a protein assay. The samples were boiled in
loading buffer, and 100 µg was loaded into the wells of
10% SDS-polyacrylamide gels. After electrophoresis, pro-
teins were electroblotted onto polyvinylidene difluoride
(Immobilon-P, Millipore, Billerica, MA, USA) membranes
overnight. Membranes were then blocked in TTBS (0.1%
[v/v] Tween 20, 100 mM Tris, 0.9% NaCl, pH 7.5) contain-
ing 5% BSA for 1 hour at room temperature and were
probed with a 1:1000 dilution of a mouse monoclonal anti-
body against cyclin E (HE12; Santa Cruz Technologies,
Santa Cruz, CA, USA). Membranes were probed with bioti-
nylated anti-mouse secondary antibodies, and bound anti-
body was detected using streptavidin-conjugated
horseradish peroxidase (HRP) and diaminobenzidine tet-
rahydrochloride colorimetric substrate (100 µl of 40 mg/ml
diaminobenzidine tetrahydrochloride, 25 µl of 80 mg/ml
NiCl2, and 1.5 µl of 30% H2O2).
Sorting and analysis of fluorescent labeled cells
Cells were harvested and resuspended in ice-cold PBS,
were fixed and permeabilized using 100% ethanol (20 min
at 4°C), and were washed with PBS. The cells were then
incubated first with primary cyclin E antibody (HE12) for 1
hour, were washed with PBS and were then incubated with
secondary anti-mouse FITC antibody for 1 hour. The cells
were then subjected to sorting with a fluorescence acti-
vated cell sorter (FACSCalibur; BD Biosciences, San Jose,
CA, USA) in the University of Michigan CCGC flow cytom-
etry core. For DNA content analysis, the fixed cells wereAvailable online http://breast-cancer-research.com/content/6/5/R531
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treated with RNase (1.0 mg/ml in PBS) for 30 min at 37°C,
were washed once with PBS and were stained in 500 µl
propidium iodide (50 µg/ml in PBS) for 15 min at room tem-
perature. Trout erythrocyte nuclei (7 × 104 nuclei/sample)
were used as an internal control. The cell cycle phase dis-
tribution was determined by analytical DNA flow cytometry.
Immunofluorescence
Cells were plated on chamber slides at 37°C overnight.
Slides were washed with PBS, were fixed with 3.7% para-
formaldehyde for 15 min at room temperature and were
washed again with PBS. Cells were incubated for 20 min
at room temperature in 5% BSA/0.1% Triton-X100 to
block nonspecific sites and to permeabilize the cells. Slides
were incubated with 100 µl of 1:1000 dilution of the cyclin
E antibody for 1 hour at 37°C, were washed and were then
incubated with 100 µl of 1:1000 dilution of secondary
FITC-conjugated anti-mouse antibody for 1 hour at 37°C.
Control cells were stained with secondary antibody alone.
Slides were washed and a cover slip was applied using
aquapolymount (Polysciences, Inc. Warrington, PA, USA).
Cyclin E was visualized by fluorescence microscopy.
Comparative genomic hybridization
The aCGH was carried out as described previously [16,17]
using arrays of BAC clones each printed in triplicate. Fluo-
rescently labeled test and reference DNAs (labeled with
either cyanine 3 (Cy3) for tumor cells or cyanine 5 (Cy5) for
normal cells) were hybridized and DNA losses, gains or
amplifications were measured by relative fluorescence
ratios.
Results
Overexpression of cyclin E in SUM149PT cells
To determine the relative levels of cyclin E in SUM149PT
cells as compared to normal cells, we began by performing
a western blot analysis on whole cell lysates using a mono-
clonal antibody directed specifically toward the C-terminus
of cyclin E protein (HE12; Santa Cruz). Cell lines used in
this experiment were SUM149PT human breast cancer
cells and MCF10A cells, a near diploid spontaneously
immortalized cell line that expresses normal cyclin E levels
[4,18].
As expected, based on published data [13], these analyses
revealed a significantly overexpressed 50 kDa cyclin E pro-
tein in SUM149PT cells when compared with MCF10A
cells (Fig. 1a). Two less abundant lower molecular weight
forms of cyclin E running at ~42 kDa and ~35 kDa were
also identified in SUM149PT cells, in agreement with pre-
vious studies showing that processing of cyclin E differs
between normal cells and breast tumor cells [19-21]. How-
ever, the question remained as to whether elevated levels
of the 50 kDa cyclin E protein in SUM149PT cells were due
to a high proportion of cells expressing normal levels of
cyclin E or to a true overexpression of the protein on a per
cell basis. In order to address this question, we performed
fluorescence-activated cell sorting analysis to measure
cyclin E levels in individual cells.
A one-parameter flow cytometric analysis was carried out
to measure the cyclin E levels of MCF10A and SUM149PT
breast cancer cells. Fixed cells were incubated in anti-
human mouse cyclin E monoclonal primary antibody and
then incubated in FITC-coupled secondary anti-mouse anti-
body. As represented by the peak in Fig. 1b, only a slightly
higher amount of FITC fluorescence was observed in the
cyclin E-positive MCF10A cells when compared with back-
ground FITC levels. Overall cyclin E levels are low in
MCF10A cells due to the fact that these cells were not syn-
chronized, and therefore only a small fraction of the popu-
lation was expressing cyclin E. In contrast, we observed an
approximately twofold to threefold cyclin E/FITC positive
peak shift in SUM149PT cells (Fig. 1b). These results sug-
gested that SUM149PT cells were expressing dramatically
increased levels of cyclin E protein when compared with
MCF10A cells, and that the proportion of cyclin E-positive
cells was also increased. An increase in peak height alone
would have indicated that more cells were expressing nor-
mal levels of cyclin E rather than overexpressing cyclin E.
These results indicate that cyclin E is overexpressed in
SUM149PT cells on a cell per cell basis.
Cyclin E is overexpressed throughout the cell cycle in 
SUM149PT cells
Due to the hCdc4 mutation in SUM149PT cells that pre-
vents targeting cyclin E for degradation, we hypothesized
that cyclin E would be overexpressed throughout the cell
cycle. To gain insight into the expression pattern of cyclin
E, two-parameter flow cytometric analysis was performed.
Proliferating MCF10A cells and SUM149PT cells were first
incubated with cyclin E monoclonal antibody and then with
FITC-coupled anti-mouse secondary antibody. The cells
were stained with 0.5 ml propidium idodide and analyzed
by flow cytometry for DNA content (Fig. 2).
The results revealed that ~38% of cycling MCF10A cells
were positive for cyclin E protein. Cells in the G1 phase
showed the highest expression and, surprisingly, cells in
the G2/M phase also showed some moderate expression of
cyclin E (Fig. 2a). In comparison, ~98% of cycling
SUM149PT cells were cyclin E-positive, including those in
the S phase, the G2 phase and the M phase of the cell cycle
(Fig. 2b). In addition, cyclin E levels in positive cells were
generally higher than in control cells, in agreement with the
results already described. These results demonstrate that
overexpression of cyclin E protein occurs in all phases of
the SUM149PT cell cycle, and that cyclin E is not being
degraded at the mid S phase.Breast Cancer Research    Vol 6 No 5    Willmarth et al.
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By examining the DNA histograms showing cell cycle pro-
gression of the MCF10A (Fig. 3a) and SUM149PT cell
lines (Fig. 3b), we found SUM149PT cells have signifi-
cantly fewer cells in the G1 phase than in MCF10A cells
(~35% versus ~67.8% in MCF10A cells). In addition,
almost one-half (~45%) of SUM149PT cells were in the S
phase while only ~8.5% of MCF10A cells were in the S
phase. These results are consistent with previous data
demonstrating an increase of G1–S phase progression in
cyclin E overexpressing HeLa cells [7]. We also observed
a sharp peak at the beginning of the S phase in SUM149PT
cells (Fig. 4b), in contrast to the flat plateau observed in the
S phase of MCF10A cells (Fig. 4a). This observation sug-
gests that SUM149PT cells progress from the G1 phase
Figure 1
Cyclin E protein is overexpressed on a per cell basis in SUM149PT cells Cyclin E protein is overexpressed on a per cell basis in SUM149PT cells. (a) HE12 cyclin E antibody was used to detect cyclin E by immunoblotting 
MCF10A and SUM149PT whole cell lysates. (b) One-parameter flow cytometric analysis was performed on fixed and permeabilized cells using 
HE12 cyclin E primary antibody and FITC secondary antibody. Cyclin E levels were twofold to threefold higher in SUM149PT cells than in MCF10A 
cells. The B gate shows the entire range of fluorescence and the C gate shows the range of fluorescence that did not overlap with the negative 
control.
(a)
(b)Available online http://breast-cancer-research.com/content/6/5/R531
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Figure 2
Cyclin E is overexpressed throughout the cell cycle in SUM149PT cells Cyclin E is overexpressed throughout the cell cycle in SUM149PT cells. Two-parameter flow cytometric analysis was performed using fixed and per-
meabilized (a) MCF10A cells and (b) SUM149PT cells. HE12 cyclin E primary monoclonal antibody and FITC-conjugated secondary antibody were 
used for cyclin E detection. Cells were incubated with 50 µg/ml propidium iodide (PI) for DNA content analysis.
Figure 3
SUM149PT cells exhibit cell cycle arrest in the S phase SUM149PT cells exhibit cell cycle arrest in the S phase. Propidium iodide staining shows that SUM149PT cells (b) have significantly fewer cells in 
the G1 phase than MCF10A cells (a). Almost 50% of cycling SUM149PT cells are in the S phase, and the sharp peak suggests that some cells are 
experiencing S-phase delay or arrest.
(a)                                                            (b)
(a)                                                   (b)Breast Cancer Research    Vol 6 No 5    Willmarth et al.
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into the S phase of the cell cycle but are unable to proceed
through the S phase when high levels of cyclin E persist,
resulting in an apparent S phase delay or arrest in these
cells.
Association between cyclin E overexpression and 
genomic instability
There is considerable evidence that constitutive overex-
pression of cyclin E accelerates the G1–S phase transition,
which can result in premature initiation of DNA synthesis.
There is also support for the hypothesis that sustained lev-
els of cyclin E may be responsible for the chromosomal
instability observed in breast cancer [8].
In order to determine whether cyclin E overexpression cor-
related with genomic instability in our panel of human
breast cancer cell lines, we utilized aCGH analysis to exam-
ine the DNA copy number alterations throughout the
genome, and utilized western blot analysis to measure cyc-
lin E protein levels. The results of these experiments are
summarized in Figs 4 and 5. SUM149PT cells, which
express the highest levels of cyclin E, also exhibited a highly
unstable genome as the aCGH analysis demonstrated
copy number alterations in virtually every chromosome.
SUM185 cells showed a similar pattern of DNA copy
number changes, but these cells expressed relatively low
levels of cyclin E, which were even lower than those in the
MCF10A control cells.
By contrast, the SUM159 cell line, which by aCGH exhib-
ited very few copy number changes characterized by two
highly focal areas of gene amplification, expressed cyclin E
levels similar to the other cell lines in the panel and signifi-
cantly lower than SUM149 cells. SUM225 cells, which
exhibited several areas of focal gene amplification and loss,
expressed similar levels of cyclin E as SUM159 cells and
other cell lines in the panel. Thus, whereas most of the
breast cancer cell lines express cyclin E levels higher then
the MCF10A cells, only the SUM149PT cells dramatically
overexpress cyclin E as a result of the hCDC4 mutation in
these cells. Furthermore, there was no simple correlation
between the levels of cyclin E expression and the degree or
type of chromosomal instability as measured by aCGH.
Cyclin E localization in SUM149PT cells
It has been well established that the endogenous full-length
form of cyclin E is predominantly nuclear in normal cells and
expressed only at the G1-S phase transition of the cell cycle
Figure 4
Genomic copy number profiles of cell lines Genomic copy number profiles of cell lines. Array comparative genomic hybridization analysis was performed on a panel of human breast cancer 
cells in order to map the DNA sequence copy number variation throughout the entire genome. The data are plotted as the log2 ratio for each BAC 
clone ordered across the genome from 1pter to Xqter. The reference DNA was male. The SUM185 cell lines (a) and SUM149PT cell lines (b) 
showed many copy number changes, while other breast cancer cells such as SUM159 cell lines (c) and SUM225 cell lines (d) had a basically nor-
mal genome with a few low-level copy number changes and focal amplifications.
(a)                                                        (b)
(c)                                                         (d)Available online http://breast-cancer-research.com/content/6/5/R531
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[3]. To determine the subcellular localization of the overex-
pressed cyclin E in SUM149PT cells, cells were cultured
on chamber slides and labeled as in previous experiments
with cyclin E primary antibody (HE12) and FITC-coupled
secondary antibody, and were visualized by fluorescence
microscopy.
The fluorescence images in Fig. 6b show cyclin E was
expressed at low levels in the nucleus of MCF10A cells, yet
not in every cell. In SUM149PT cells (Fig. 6d), cyclin E pro-
tein overexpression was observed in the nucleus of every
cell and some expression was also observed in the
cytoplasm.
Discussion
Cyclin E overexpression in hCdc4 mutant breast cancer 
cells
Our results, and data from other studies employing meth-
ods to inhibit the hCdc4 protein, show that hCdc4 plays a
major role in cyclin E degradation. It has been demon-
strated by others that hCdc4 mutations stabilize cyclin E in
drosophila and yeast [13,22]. A number of human cancers
such as ovarian cancer, breast cancer and endometrial
cancer have also been shown to possess hCdc4 mutations
as well as high levels of cyclin E [13,22,23]. However, it
was not understood until now whether cyclin E is being
maintained at normal levels throughout the cell cycle or is
actually accumulating during the cell cycle in tumors with
inactivating hCdc4 mutations.
We examined the cyclin E levels of an hCdc4 mutant
human breast cancer cell line, SUM149PT, and found that
cyclin E was overexpressed with levels up to threefold
greater than normal cells on a per cell basis. Cyclin E over-
expression in these cells was not restricted to the G1-S
phase transition where cyclin E is normally expressed, but
instead occurred at stabilized levels throughout the cell
cycle. Cyclin E is therefore not being properly regulated in
these cells, most probably due to the fact that hCdc4 can-
not target cyclin E for degradation. Since the hCdc4 F-box
protein has proven to be the determining factor regulating
cyclin E degradation [24], our results give further support
to the notion that hCdc4 may act as a tumor suppressor.
SUM149PT cells had a high number of cells in the S phase
of the cell cycle, consistent with previous data showing that
cyclin E overexpression accelerates the G1-S phase transi-
tion [7]. We show that in contrast to the plateau observed
in the S phase of normal cells, SUM149PT cells have an
abnormal DNA histogram characterized by a large S phase
peak (Fig. 3b). This S phase delay or arrest suggests that
these cells are unable to progress through the S phase,
which may be due to the fact that high cyclin E levels per-
sist. This has been demonstrated by previous experiments
in which constitutive cyclin E expression induced S phase
arrest in normal HME cells [8]. In addition, we showed that
cyclin E localization in the SUM149PT cells is predomi-
nantly but not exclusively nuclear. It is not clear at this point
why some cyclin E is observed in the cytoplasm of
SUM149PT cells.
The many genome copy number changes observed in
SUM149PT cells may be directly associated with cyclin E
overexpression. The G1 checkpoint is critical to prevent
genomic instability by regulating DNA repair and progres-
sion through the cell cycle. It is therefore possible that
overexpressing cyclin E may potentiate chromosomal insta-
bility by virtue of premature phosphorylation of its sub-
strates and replication of damaged DNA. Indeed, it has
been shown that overexpressing cyclin E induces chromo-
somal aneuploidy in HME cells and colorectal cancer cells
[8,25]. On the contrary, we found no direct correlation
between cyclin E overexpression and chromosomal insta-
bility in a panel of other breast cancer cells lines we exam-
Figure 5
Cyclin E expression in a panel of breast cancer cell lines Cyclin E expression in a panel of breast cancer cell lines. Analysis of cyclin E levels in normal cell lines versus tumor breast epithelial cell lines using 
HE12 cyclin E antibody for immunoblotting.Breast Cancer Research    Vol 6 No 5    Willmarth et al.
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ined. Lung and colleagues had previously examined primary
tumor tissues from 71 patients with breast cancer, and they
also found no direct correlation between cyclin E overex-
pression and chromosomal genomic instability [26].
Conclusions
We have shown that SUM149PT cells, which possess a
mutation in the hCdc4 subunit of the SCF ubiquitin ligase,
are unable to regulate cyclin E expression. In fact, cyclin E
is present at elevated but stable levels on a cell per cell
basis for the duration of the cell cycle in these cells. When
compared with a panel of other breast cancer cell lines,
cyclin E is expressed at the highest levels in SUM149PT
cells. In addition, immunofluorescence showed that cyclin
E is being expressed in both the cytoplasm and nucleus of
SUM149PT cells, in contrast to expression only in the
nucleus of MCF10A cells.
Cyclin E overexpression has previously been implicated as
a cause of genomic instability in normal HME cells [8]. The
aCGH data demonstrate that SUM149PT cells have a high
number of chromosomal aberrations throughout their
genome. We cannot say for certain, however, that there is
a cause and effect relationship between expression of cyc-
lin E and genomic instability in the SUM149PT cells, since
we observed breast cancer cell lines with many chromo-
somal aberrations that showed both low and high cyclin E
levels. Cyclin E overexpression is thus probably only one of
many factors that contribute to genomic instability in human
breast cancer.
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